Halidou Tinto

Infectiology — Institut de Recherche en Sciences de la Santé, Burkina Faso

LeadR Profile

1 643 ScienceLeadR Reputation 1643
Network Map

Infectiology

Subspecialties: Public Health - Pharmacy - Obstetrics

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Short Biography

Pharm D and Medical scientist by background, Halidou Tinto is the Regional Director of the Institute for Health Sciences research (IRSS) in Nanoro, Burkina Faso. He is widely recognised as a leader in successfully evaluating the safety and efficacy of drugs and vaccines against malaria, the major cause of disease and death amongst children in Africa. After a PhD at the Intitute of Tropical Medicine of Antwerp (ITM) in Belgium, he founded the Clinical Research Unit of Nanoro (CRUN - www.crun.bf) in Burkina Faso in 2009. From 10 people at its creation, CRUN has steadily expanded to over 400 employees and students and is now the exemplar of an outstanding African institution created and led by an African scientist and a leading centre for training young scientists and clinicians in the design and conduct of clinical trials. Prof. Tinto has made several key contributions towards the development and deployment of the current two licensed malaria vaccines (RTS,S & R21) and is making a major contribution towards testing the next generation of vaccines. He is member of the African Academy of Science (AAS) and the National Academy of Science and Arts in Burkina Faso (ANSAL-BF). He was recognised in late 2021 as one of the African Game Changers of the Year by the journal Jeune Afrique and was listed in December 2023 among Nature journal’s top 10 individuals who had helped to make outstanding discoveries and bring attention to crucial issues in the world. Most recently in 2024, he was jointly awarded the title of Honoris Doctorate by the Universities of KU-Leuven and UL-Louvain in Belgium. He published over 400 articles in peer-reviewed journals.

Organizations

Career arc: 2001 - 2026

Source: PubMed

Institut de Recherche en Sciences de la Santé

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 414

Citations

Citations: 11 807 1st author: 19 Last author: 66 Unique author: 0


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Safety, pharmacokinetics, and antimalarial efficacy of single-dose cabamiquine-pyronaridine combination therapy for the treatment of adults and adolescents with acute uncomplicated Plasmodium falciparum malaria (CAPTURE 1): a prospective, multicentre, open-label, phase 2a study.
malaria, safety, malaria, falciparum, drug-related side effects and adverse reactions, adolescent, parasites, therapeutics, antimalarials, communicable diseases, pharmacokinetics
Lancet Infect Dis Top journal20263
Genotypic analysis of Plasmodium falciparum malaria parasites in a clinical trial of RTS,S vaccination in combination with seasonal malaria chemoprevention.
malaria, vaccines, chemoprevention, malaria, falciparum, vaccination, prevalence, parasites, infections
Malar J20260
Healthcare workers' knowledge and acceptance of the malaria vaccine in the Nanoro Health District of Burkina Faso: a cross-sectional study.
malaria, cross-sectional studies, malaria vaccines, vaccines, vaccination, health personnel, child
Malar J20260
Improving the field accuracy of a malaria diagnostic algorithm combining sequential interpretation of rapid diagnostic test detecting PfHRP2 and pLDH in febrile children in a seasonal hyperendemic malaria transmission area in Burkina Faso.
malaria, algorithms, microscopy, diagnosis, therapeutics, antimalarials, infections, child
PLoS One20260
Advances in the development of malaria vaccines.
malaria, malaria vaccines, vaccines, research
BMJ Top journal20262

Clinical Studies 44

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 8 Study Director: 1

By phase:

Phase 3 15
N/A 12
Phase 2 6
Phase 4 5
Phase 2/Phase 3 3
Phase 1/Phase 2 2
Phase 1 1

By status:

Completed 33
Recruiting 5
Active not recruiting 2
Terminated 2
Unknown 2

By type:

Interventional 39
Observational 5

By Monocentric/Multicentric:

monocentric 17
multicentric2to4 11
multicentric5to9 11
multicentricup10 5

Main Topics

Ongoing Clinical Trials

5 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Assessing Vaccine Effectiveness of R21 Matrix M Across Malaria Transmission Settings (AVERT)
NCT07749911 — research design, malaria, immunization, malaria vaccines, vaccines, immunization programs, classification, malaria, falciparum, vaccination, microscopy, records, child
N/ARecruiting2026
A Study to Assess the Experimental Malaria Vaccines R78C and RH5 1 With Matrix M in Combination With R21 Matrix M
NCT07183371 — hepatitis b surface antigens, cells, malaria, serum albumin, staphylococcal protein a, malaria vaccines, safety, serum, powders, vaccines, meningococcal vaccines, excipients, hepatitis a virus, glycine, malaria, falciparum, meningitis, solutions, aged, rabies, viruses, antibodies, monoclonal, hepatitis a, sucrose, serum albumin, human, hepatitis a vaccines, hepatitis, child, adjuvants, vaccine, men
Phase 2Active not recruiting2025
A Study to Assess the Experimental Malaria Vaccines R78C and RH5 1 Combined With R21 Matrix M (a Multi stage Malaria Vaccine)
NCT06958198 — hepatitis b surface antigens, malaria, staphylococcal protein a, malaria vaccines, safety, vaccines, multiple chronic conditions, malaria, falciparum, aged, antibodies, monoclonal, child, adjuvants, vaccine
Phase 1Recruiting2025
An Observational Study to Assess Effectiveness and Safety of The R21 Matrix M Malaria Vaccine
NCT07009847 — malaria, malaria vaccines, safety, vaccines, case-control studies, malaria, falciparum, child
N/ARecruiting2025
Seasonal R21 Mass Vaccination for Malaria Elimination
NCT06578572 — malaria, malaria vaccines, vaccines, incidence, vaccination, mass vaccination, prevalence, seasons, infections, child
Phase 3Recruiting2024

LeadR Networks

Main global connection map